Letter to Editors

Acute respiratory distress syndrome from Covid-19: A perfect storm from free radicals? Proposal for a new treatment

Dear Editor

The Covid-19 epidemic transformed life in our cities and continues to cause numbers of deaths. Although it often occurs in mild form, cases that develop acute respiratory distress syndrome (ARDS), cardiovascular damage, shock, or multi-organ dysfunction are frequent and indicate a systemic inflammatory response [1].

The inflammatory response is triggered by activation of monocytes and alveolar macrophages, which produce, and release into the extracellular compartment, bioactive mediators including reactive oxygen species (ROS), reactive nitrogen species (RNS), and cytokines. When the production of these mediators exceeds the capacity of tissues to neutralize them, oxidative stress occurs, and is a major contributor to alveolar cell death and endothelial injury. Damage to the vascular endothelium can lead to multi-organ dysfunction [2]. This inflammatory response is common to many diseases, including septic shock [3]. Drugs that combat the cytokine storm (anakinra, tocilizumab) have been proposed for the treatment of Covid-19-related ARDS [4], but other therapeutic strategies need to be explored.

Data from animal studies indicate that ROS and RNS play fundamental roles in the pathogenesis of ARDS [5], and high levels of RNS are involved in the multi-organ failure of septic shock [6]. Nevertheless, drugs that minimize the harmful effects of these species have not been introduced into clinical practice. Methylene blue, an old anti-malarial drug currently used to treat methemoglobinemia, has been used successfully to treat septic shock [7] with minimal adverse effects. It acts effectively as an antioxidant on RNS by lowering the bio-availability of nitric oxide [8], which is the progenitor of strongly oxidative nitrogen-based molecules. Methylene blue also prevents ROS production by inhibiting the action of xanthine oxidase [9].

Based on these data methylene blue appears worth trying to contrast Covid-19-related pneumonia when the first symptoms of ARDS appear. As regards dose, methylene blue was administered at 1–2 mg/kg in a single bolus or lower dose infusion in septic shock patients; methylene blue has a dose-dependent effect on pulmonary vascular resistance, and venous infusion of doses above 2 mg / kg should be prudently avoided [10]. Continuous infusion would allow for titration based on response

and result in a lower dose overall. We therefore suggest that, similarly to what was experienced in septic shock [11], a bolus of 1 mg/kg, followed after 2 h by infusion of 0.5 mg/kg/h for four hours would be an appropriate starting point. The earlier the start of treatment, the better the expected result, and taking low-dose methylene blue (120–180 mg/day orally for ten or fifteen days) from the first Covid-19 symptoms could prevent the onset of ARDS and avoid the need for hospitalization.

Authorship

Giulio Scigliano: conception and design of the study, drafting of article, analysis and interpretation of data, final approval of the version to be submitted.

Giuseppe Augusto Scigliano: acquisition of data, analysis and interpretation of data, final approval of version to be submitted.

None of the authors has any conflict of interest to disclose.

Funding source

None.

Ethical approval

Not applicable.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Han S, Mallampalli RK. The acute respiratory distress syndrome: from mechanism to translation. J Immunol 2015;194(3):855–60. https://doi.org/10.4049/jimmunol.1402513.

[2] Ince C, Mayeux PR, Nguyen T, et al. The endothelium in sepsis. Shock 2016;45:259–70. https://doi.org/10.1097/SHK.0000000000000473.

[3] Prauchner CA. Oxidative stress in sepsis: Pathophysiological implications justifying antioxidant co-therapy. Burns 2017;43(3):471–85. https://doi.org/10.1016/j.burns.2016.09.023. Epub 2016 Dec 27.

[4] Mehta P, Mc Auley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033–4. https://doi.org/10.1016/S0140-6736(20)30628-0.

[5] Fink MP. Role of reactive oxygen and nitrogen species in acute respiratory distress syndrome. Curr Opin Crit Care 2002;8(1):6–11.

[6] Groeneveld PH, Kwappenberg KM, Langermans JA, Nibbering PH, Curtis L. Nitric oxide (NO) production correlates with renal insufficiency and multiple organ dysfunction syndrome in severe sepsis. Intensive Care Med 1996;22(11):1197–202. https://doi.org/10.1007/bf01709336.

[7] Andresen M, Dougnac A, Díaz O, et al. Use of methylene blue in patients with refractory septic shock: impact on hemodynamics and gas exchange. J Crit Care 1998;13(4):164–8.

[8] Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol 1993 Jan 26;45(2):367–74.

[9] Salaris SC, Babbs CF, Voorhees III WD. Methylene blue as an inhibitor of superoxide generation by xanthine oxidase. Biochem Pharmacol 1991;42(3):499–506.

[10] Juffermans NP, Vervloet MG, Daemen-Gubbels CR, Binnekade JM, de Jong M, Groeneveld AB. A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. Nitric Oxide 2010;22(4):275–80. https://doi.org/10.1016/j.niox.2010.01.006.

[11] Abd-Alhameed AE, Hamed AMS, Omran AS. Methylene blue: Role in early management of septic shock patients? Shams J Anaesthesiol 2014;7(3):327–35. https://doi.org/10.4103/1687-7934.139558.

Giulio Scigliano*, Giuseppe Augusto Scigliano
National Neurological Institute C. Besta, via G. Celoria 11. 20133 Milan, Italy
E-mail address: giulioscigliano@gmail.com (G. Scigliano).

---

* Corresponding author at: via Padova 113, 20127 Milan, Italy.